Sign In
Buy NVO
$48.03
+0.385 (+0.81%)
At Close: Jun 26, 2026
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed a
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
02:56pm, Tuesday, 11'th Mar 2025
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
01:44pm, Tuesday, 11'th Mar 2025
Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
01:00pm, Tuesday, 11'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
12:23pm, Tuesday, 11'th Mar 2025
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ: NVO). Such investors are advis
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO
11:30am, Tuesday, 11'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
11:05am, Tuesday, 11'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordi
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
09:45am, Tuesday, 11'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
09:10am, Tuesday, 11'th Mar 2025
SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NV
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
08:35am, Tuesday, 11'th Mar 2025
On Monday, Novo Nordisk A/S NVO announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders
06:30pm, Monday, 10'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and Dece
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
